Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study
Status:
Completed
Trial end date:
2018-09-21
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate whether hypoglycaemia observed after food intake
in bariatric patients can be either influenced by an SGLT2 inhibitor, empagliflozin, or via
inhibition of inflammation with an human interleukin-1 receptor antagonist (IL1-RA,
anakinra).
Phase:
N/A
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Treatments:
Empagliflozin Interleukin 1 Receptor Antagonist Protein